Hori­zon touts PhIV win for Te­pez­za; FDA sets ad­comm dates for Sarep­ta, Pfiz­er, Ei­sai apps

Hori­zon Ther­a­peu­tics’ Te­pez­za, which treats a rare au­toim­mune dis­ease that af­fects the eye, has cleared a Phase IV tri­al de­signed to il­lus­trate the drug’s use …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER